Autolus Therapeutics plc (AUTL) has entered 2026 with clear momentum, driven by the commercial progress of its first approved therapy, AUCATZYL (obe-cel), and a pipeline that continues to expand into new indications. With sales in its debut year surpassing expectations, regulatory approvals secured across major markets, and multiple clinical programs advancing toward pivotal stages, the company is shaping a path that combines near-term revenue growth with long-term opportunities. These developments make AUTL a stock that stands out at this moment, supported by both commercial traction and scientific progress.
Momentum Drivers & Upcoming Milestones
For comments and feedback contact: editorial@rttnews.com
September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.